We are live on ! Find out more
BLTE

Belite Bio
BLTE

11 hedge funds and large institutions have $2.23M invested in Belite Bio in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.37% less ownership

Funds ownership: 0.56% → 0.2% (-0.37%)

35% less funds holding

Funds holding: 17 → 11 (-6)

69% less capital invested

Capital invested by funds: $7.1M → $2.23M (-$4.87M)

75% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 8

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 6

Holders
11
Holders Change
-6
Holders Change %
-35.29%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$44.8K
2
GI
GAMMA Investing
California
+$1.57K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.65M
2
Morgan Stanley
Morgan Stanley
New York
-$731K
3
JP Morgan Chase
JP Morgan Chase
New York
-$609K
4
CSS
Cubist Systematic Strategies
Connecticut
-$541K
5
Marshall Wace
Marshall Wace
United Kingdom
-$243K

BLTE Hedge Fund Activity: Q1 2024 in Review

11 of the 6,959 institutional investors tracked by Wall St. Rank reported a position in Belite Bio (BLTE) for Q1 2024, worth a combined $2.23M — down 69% from $7.1M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of BLTE and 0 opened new positions — a net loss of 6 holders — while 8 trimmed existing stakes and 2 added.

The largest buyer was Point72 Asset Management, adding an estimated $44.8K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.65M sold.

  • 11 institutional investors held Belite Bio (BLTE) as of Q1 2024, down from 17 in Q4 2023.
  • Funds reported $2.23M of Belite Bio stock for Q1 2024, down 69% quarter-over-quarter.
  • 0 funds opened new Belite Bio positions in Q1 2024 and 6 closed out, a net change of -6 holders.
  • The largest Belite Bio buyer in Q1 2024 was Point72 Asset Management, an estimated $44.8K added.
  • The largest Belite Bio seller in Q1 2024 was Armistice Capital, an estimated $1.65M sold.

Based on aggregated 13F filings for Q1 2024.